Flexible solutions. Responsive teams. Data-driven insights.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBS
This white paper discusses partnering solutions that are specifically tailored for emerging biopharma. Given tremendous advances in this segment of the overall biopharmaceutical market, even though each company may only have one or two assets, the total pipeline is equivalent to roughly two-thirds of the entire global industry pipeline. Emerging biopharma is well served by fully collaborative outsourcing arrangements with service providers. In an increasingly complex drug development and healthcare environment, it is extremely important for companies to be able to demonstrate value, even if their intention is to be acquired or to out-license their asset following proof-of-concept. Transitioning from transactional to fully integrated outsourced partnering options can be extremely beneficial in this regard, since it enables the company to leverage their partner’s therapeutic expertise, resourcing capabilities, and organizational infrastructure.
Today, EBP (emerging biopharma) organizations play an increasingly crucial role in bringing new therapies, devices and diagnostics to healthcare providers and patients across a range of therapeutic areas and unmet medical need.
EBP companies typically have a laser focus on one or two assets, ranging from start-up to more mature, and formal to virtual organizations. Their pipelines are robust, with over 4,700 drug indication programs under development, equivalent to 71% of the entire global industry pipeline according to a recent BIO Industry analysis.
With EBP companies serving as a high-growth innovation engine, large and mid-biopharma organizations, public and private investors and other stakeholders are demanding a strong strategy aimed at demonstrating, driving and delivering the highest possible return on investment. The modern day EBP executive team seeking novel approaches to achieve this is increasingly exploring fully collaborative outsourcing arrangements with service providers as a major component of their overall organizational strategy.
This paper is the first part of a series of articles aimed at helping the EBP executive and his/her team members better assess the value of a “partnered” outsourcing approach across the continuum of development and commercialization, and potential approaches to mapping out the right fit for their organizational needs. Throughout this paper the term “partnered” is used to describe collaborative service engagements between EBPs and global clinical development and commercial service providers, and should not be misinterpreted as a financial investment by a service provider.
Operating a start-up, or even relatively mature but still small EBP organization, carries a tremendous weight and wide range of responsibilities. The EBP executive and his or her team are typically “betting the farm” on a singular indication or therapeutic area, a limited number of assets, and a small, highly dedicated organization. This comes with certain advantages – streamlined infrastructure and nimbleness, for example – but also presents unique challenges, i.e., limited/constrained resourcing, expertise gaps in clinical and commercial functions and ability to scale processes and relationships across programs, just to name a few.
EBPs are developing clinical assets through much later stages of development, and in those cases where it has entered into a partnership with larger pharma companies, these organizations are now being asked to carryout Phase II and Phase III development rather than integrating or jointly developing with the larger organization.
Even if the intention is to be acquired or to out-license following proof of concept, the need for strong clinical trial data is essential for sharing with prospective partners. The multi-layered body of evidence required to substantiate a minimal level of value, and even more to substantiate a comprehensive value story in the most compelling manner, spans all phases of development.
Flexible solutions. Responsive teams. Data-driven insights.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.